Early efficacy of tamsulosin versus terazosin in the treatment of men with benign prostatic hyperplasia: A randomized, open-label trial

Journal of Applied Research

Volumn 5, Issue 2, 2005, Pages 237-245

  Narayan, Perinchery ^a   O'Leary, Michael P ^b   Davidai, Giora ^c  

^a North Florida Urology Associates   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Benign prostatic hyperplasia; Symptom severity; Tamsulosin; Terazosin

Indexed keywords

TAMSULOSIN; TERAZOSIN;

ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; EJACULATION DISORDER; FATIGUE; HEADACHE; HUMAN; HYPOTENSION; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCORING SYSTEM; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SUPRAVENTRICULAR TACHYCARDIA; SYNCOPE; UPPER RESPIRATORY TRACT INFECTION;

EID: 21844437943     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Schulman C. Benign prostatic hypertrophy: which treatment, for whom? Rev Med Brux. 1999;20:A212-A218.
2. 1A- adrenoceptor antagonist. Eur Urol. 1996;29:155-167.
3. 1-adrenergic receptor subtypes. Prostate. 1997;33:55-59.
4. Barry M, Roehrborn C. Management of benign prostatic hyperplasia. Annu Rev Med. 1997;48:177-189.
5. 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol. 1997;80:606-611.
6. de Mey C, Michel MC, McEwen J, Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol. 1998;33: 481-488.
7. 1-adrenergic blocking drugs. Drug Saf. 1994;11:12-20.
8. Lepor H, for the Tamsulosin Investigator Group. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology. 1998;51:892-900.
9. Bruskewitz R. Management of symptomatic BPH in the US: who is treated and how? Eur Urol. 1999;36(suppl 3):7-13.
10. Barry MJ, Fowler FJ Jr, O'Leary MP, et al, and the Measurement Committee of the American Urological Association. The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol. 1992;148:1549-1557.
11. Barry MJ, Fowler FJ, O'Leary MP, et al, for the Measurement Committee of the American Urological Association. Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care. 1995;33(suppl 4):AS145-AS155.
12. Narayan P, Bruskewitz R. A comparison of two phase III multicenter, placebo-controlled studies of tamsulosin in BPH. Adv Ther. 2000;17:287-300.
13. Narayan P. Lepor H. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology. 2001; 57:466-470.
14. 1-Adrenergic receptor subtypes in human detrusor. J Urol. 1998;160:937-943.
15. 1d subtype in filling symptoms and effects of ageing on vascular expression. BJU Int. 2000;85(suppl 2): 6-11.
16. 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol. 1994;113:723-728.